{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Franchi M"],"funding":["Regione Autonoma della Sardegna","Agenzia Italiana del Farmaco, Ministero della Salute"],"pagination":["2040620721996488"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7905486"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12"],"pubmed_abstract":["<h4>Introduction</h4>Randomized clinical trials showed that bortezomib, in addition to conventional chemotherapy, improves survival and disease progression in multiple myeloma (MM) patients not eligible for stem cell transplantation. The aim of this retrospective population-based cohort study is the evaluation of both clinical and economic profile of bortezomib-based <i>versus</i> conventional chemotherapy in daily clinical practice.<h4>Methods</h4>Healthcare utilization databases of six Italian regions were used to identify adult patients with non-transplant MM, who started a first-line therapy with bortezomib-based or conventional chemotherapy. Patients were matched by propensity score and were followed from treatment start until death, lost to follow-up or study end-point. Overall survi"],"journal":["Therapeutic advances in hematology"],"pubmed_title":["Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project."],"pmcid":["PMC7905486"],"funding_grant_id":["H56J16000500005","H56D15000030005"],"pubmed_authors":["Vener C","Di Martino M","Stival C","Garau D","Scondotto S","Romero M","Franchi M","De Carlo I","Della Porta MG","Passamonti F","Kirchmayer U","Corrao G"],"additional_accession":[]},"is_claimable":false,"name":"Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project.","description":"<h4>Introduction</h4>Randomized clinical trials showed that bortezomib, in addition to conventional chemotherapy, improves survival and disease progression in multiple myeloma (MM) patients not eligible for stem cell transplantation. The aim of this retrospective population-based cohort study is the evaluation of both clinical and economic profile of bortezomib-based <i>versus</i> conventional chemotherapy in daily clinical practice.<h4>Methods</h4>Healthcare utilization databases of six Italian regions were used to identify adult patients with non-transplant MM, who started a first-line therapy with bortezomib-based or conventional chemotherapy. Patients were matched by propensity score and were followed from treatment start until death, lost to follow-up or study end-point. Overall survi","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-04T22:01:20.964Z","creation":"2025-04-04T22:01:20.964Z"},"accession":"S-EPMC7905486","cross_references":{"pubmed":["33747423"],"doi":["10.1177/2040620721996488"]}}